ImmunityBio announced the initial treatment of multiple patients in the United States to receive therapy with ANKTIVA, ImmunityBio’s recently approved immunotherapy for Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer carcinoma in situ. ANKTIVA was approved by the U.S. Food and Drug Administration, FDA, on April 22, 2024 for the treatment of patients with BCG-unresponsive NMIBC CIS with or without papillary tumors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- Largest borrow rate increases among liquid names
- ImmunityBio finishes GMP drug substance manufacturing for 170K Anktiva doses
- ImmunityBio call volume above normal and directionally bullish
- ImmunityBio, Serm Institute of India enter BCG supply arrangement
- ImmunityBio price target raised to $6 from $5 at Piper Sandler